Supernus Pharmaceuticals Set to Reveal Q2 2025 Results Soon

Supernus Pharmaceuticals to Showcase Q2 Financial Outcomes

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a leading biopharmaceutical firm, is preparing to announce its financial and operational results for the second quarter of 2025. Investors and stakeholders can expect the report to be available after market hours on an upcoming Tuesday, with a date soon approaching.

Accessing the Conference Call

On the day of the announcement, Jack Khattar, the President and CEO of Supernus, along with Tim Dec, the Senior Vice President and CFO, will guide a comprehensive conference call. This session is scheduled to take place at 4:30 PM ET, where management will share both financial and business developments while also fielding questions from participants.

Participating in the Call

Investors wishing to engage in the discussion can pre-register through the company’s Investor Relations portal. Post-registration will provide the necessary dial-in details and a personal conference code. It's advisable for participants to join the call a quarter of an hour prior to its commencement to ensure a smooth experience.

Post-Call Replay Availability

For those unable to attend live, a replay of the call will be accessible on the Investor Relations section of Supernus’ website for a period of 60 days following the event. This service ensures that all interested parties can stay updated on the company's progress and insights shared during the call.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals is dedicated to creating and commercializing innovative products specifically aimed at treating central nervous system (CNS) diseases. The company boasts a diverse portfolio focusing on conditions such as attention-deficit hyperactivity disorder (ADHD), migraine, epilepsy, and Parkinson’s disease, among others.

Focus on CNS Treatments

The company is not only expanding its existing product line but also actively developing a range of new candidate treatments that promise to address various CNS challenges. This initiative highlights Supernus's commitment to improving patient outcomes and enhancing the quality of life for individuals facing neurological disorders.

Investor Relations and Contact Information

For more details regarding financial updates and product developments, stakeholders are encouraged to visit Supernus’ official website. The site provides essential insights into the company’s ongoing projects, investor materials, and other essential updates.

Investor Contacts

Individuals looking to reach out regarding investment inquiries can contact:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591

Additionally, for further investor communication, connect with Peter Vozzo from ICR Healthcare at (443) 213-0505 or through email.

Frequently Asked Questions

1. What is Supernus Pharmaceuticals known for?

Supernus Pharmaceuticals is a biopharmaceutical company focusing on the treatment of central nervous system (CNS) diseases, developing innovative therapies for a range of conditions.

2. When will the Q2 2025 financial results be announced?

The financial results for the second quarter of 2025 are expected to be released after market close on an upcoming Tuesday.

3. Who will lead the conference call?

Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will lead the conference call to discuss financial outcomes and answer questions.

4. Where can I access the webcast of the call?

A live webcast will be available in the Events & Presentations section of Supernus' Investor Relations website, and a replay will be accessible for 60 days after the call.

5. How can I contact Supernus Pharmaceuticals Investor Relations?

Investors can contact Jack A. Khattar or Peter Vozzo for inquiries regarding investment and clinical developments at the provided contact numbers.

About The Author

Riley Hayes here, a financial writer and specialist committed to assisting individuals in navigating the intricate world of finance. My love is using my blog and articles to simplify complex financial ideas into understandable, doable guidance. Having worked in finance for many years, I try to give my readers the information and resources they need to make wise financial choices.

Writing for several financial blogs has let me connect with a wide range of readers, from novice investors seeking new ideas to seasoned investors. My mission is to make money interesting and approachable so you may take charge of your financial future. I appreciate you traveling with me toward success and financial literacy.

Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.